NovaBay Pharma Revenue, Profits - NBY Quarterly Income Statement

Add to My Stocks
$1.4 $0.05 (3.7%) NBY stock closing price Sep 19, 2018 (Closing)

Fundamental analysis of NBY stock involves analyzing its financial statements, apart from checking the NovaBay Pharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $2.79M for 2018 Q2 impacts the NBY stock. Investors typically check year over year or quarter over quarter revenue growth. Revenue for year 2018 Q2 is $2.79M and has decreased from $2.95M quarter on quarter as is evident when you compare the latest figures in the latest NovaBay Pharma profit and loss statement with those of the prior corresponding period. Also see NovaBay Pharma assets and NovaBay Pharma free cash flow for a complete valuation of NBY stock.

View and download details of revenue and profits for NovaBay Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
NovaBay Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
NovaBay Pharma Gross Profit
Research & Development Expense----------
Selling General & Admin Expense4.34M5.01M4.81M5.6M5.11M6.82M5.26M4.88M4.11M4.79M
Income Before Depreciation Depletion Amortization-2.08M-2.36M--2.16M-1.75M-3.77M-2.15M-2.01M-2.2M-4.62M
Depreciation Depletion Amortization----------
Non Operating Income----0.27M--0.23M--1.72M-0.48M-0.45M
Interest Expense----------
NovaBay Pharma Pretax Income
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-1.59M-2.15M--2.45M-1.74M-4.01M-1.65M-3.74M-2.69M-5.08M
Extraordinary Items & Discontinued Operations----------
NovaBay Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS17.29M16.67M16.02M15.32M15.31M15.28M15.46M10.91M7.41M4.09M
Average Shares used to compute Basic EPS17.09M16.41M15.38M15.32M15.31M15.28M15.15M10.91M7.41M4.09M
Income Before Nonrecurring Items-2.08M-2.15M--2.45M-1.74M-4.01M-1.65M-3.74M-2.69M-4.69M
Income from Nonrecurring Items----------0.39M
NovaBay Pharma Earnings Per Share Basic Net
NovaBay Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.15-0.140.02-0.16-0.11-0.26-0.13-0.34-0.36-1.15
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on NovaBay Pharma stock analysis. It helps to look at the following income statement items:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that NBY stock has a topline or revenue of $2.79M for 2018 Q2 as per this NovaBay Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-1.59M for NBY stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called statement of revenue and expense. The NBY financials along with NovaBay Pharma historical stock prices provide a lot of details about the firm.

NovaBay Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield